Gewinn- und Verlustrechnung von AST SpaceMobile, Inc.

Shares of SpaceX (NASDAQ:SPCX) are down 6% to $151 and change in midday trading Tuesday, an unusual response given the flood of bullish analyst initiations that hit the tape today and the company's

ASTS faces macro headwinds, rivals like Starlink and falling estimates, yet a three-satellite Bluebird launch this month could shift the story.

The question is what happens when the short sellers get the story wrong. The answer is often a sharp stock price correction.

SpaceX does everything from orbital launches to mobile broadband to artificial intelligence to owning X (formerly known as Twitter). Its satellite-to-surface broadband arm, however, faces new and motivated competition.

The latest trading day saw AST SpaceMobile, Inc. (ASTS) settling at $80.64, representing a -5.27% change from its previous close.

Shares of space stocks are selling off across the board midday Monday, with the group's leaders giving back a chunk of last week's sharp gains.

AST SpaceMobile rocketed higher this week after Rocket Lab announced it was acquiring Iridium in an $8 billion deal. The valuation premium Rocket Lab is paying to acquire Iridium has investors feeling more bullish about AST stock.

The first half of the trading year typically operates on a dominant market narrative. Over the past six months, that narrative has favored massive artificial intelligence (AI) and compute infrastructure rallies.

AST SpaceMobile is a public venture-stage infrastructure play, targeting direct-to-phone satellite connectivity as a wholesale layer for mobile network operators. ASTS's investment case hinges on technical execution, major MNO partnerships, regulatory wins, and a scalable partner-driven revenue model, not current financials. With $3.5B in cash, FCC authorization, and a 2026 deployment plan, ASTS is positioned for commercial activation but faces execution and competitive risks.

After space stocks were battered in the wake of the SpaceX NASDAQ: SPCX IPO in June, AST SpaceMobile rewarded patient investors with its best daily performance in two years.